PRESCRIRE'S RATINGS
Our ratings indicate whether a product represents a therapeutic advance in the relevant clinical situation. We consider not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
|
 |
BRAVO
The product is a major therapeutic advance in an area where previously no treatment was available.
|
 |
A REAL ADVANCE
The product is an important therapeutic advance but has certain limitations.
|
 |
OFFERS AN ADVANTAGE
The product has some value but does not fundamentally change current therapeutic practice.
|
 |
POSSIBLY HELPFUL
The product has minimal additional value, and should not change prescribing habits except in rare circumstances.
|
 |
NOTHING NEW
The product has not been shown to represent a therapeutic advance.
|
 |
NOT ACCEPTABLE
Product without evident benefit but with potential or real disadvantages.
|
 |
JUDGEMENT RESERVED
The editors postpone their rating until better data and a more thorough evaluation of the product are available.
|
The Prescrire Drug Awards for 2024
Download the full article:

"The Prescrire Awards for 2024" Prescrire Int 2025; 34 (270): 136-139. FREE.
Back to "The Prescrire Awards for 2024"

Enjoy full access to Prescrire International, and support independent medical information
|